A leading RNAi therapeutics company.

ALN-TTR02 utilizes the business’s proprietary second-generation lipid nanoparticle technology using the ‘MC3′ lipid. Alnylam expects to provide data out of this study in the 3rd quarter of 2012. Certainly, ALN-TTR02 is our business lead program in this work and we expect to initiate a Stage II trial afterwards this year, followed by a pivotal trial beginning in 2013,’ said Akshay K. Vaishnaw, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Alnylam. ‘ALN-TTR02 utilizes our proprietary second-era LNP technology which has shown significant potency improvements in both pre-clinical and scientific studies. We very much anticipate our anticipated reporting of TTR knockdown data from the Stage I study in the third quarter of this season.’ Related StoriesResearchers identify tumor suppressor genes that drive subset of melanomasPerisylvian polymicrogyria gene foundUnderstanding how schizophrenia affects workings of the mind’RNAi therapeutics represent a novel and fascinating approach for the treatment of ATTR, as this brand-new drug modality has the potential to make a meaningful influence in the treating this devastating disease.There have been 1,934,598 admissions to, transfers within, or discharges from these units and 8,318,675 patient-days . Active Surveillance A total of 1 1,712,537 surveillance screening tests were obtained during the analysis period from individuals who were admitted to or transferred or discharged from acute care facilities nationwide . During this period, the %age of individuals who were screened at admission improved from 82 percent to 96 percent, and the %age who have been screened at transfer or discharge elevated from 72 percent to 93 percent among Patients Admitted to and Those Transferred or Discharged from Acute Care Veterans Affairs Medical Units Nationwide.).7 percent .